Therapixel Closes €15M Series B Financing


Therapixel, Nice, Paris-France- and Chicago, IL-based company focused on the design and commercialization of AI-powered medical imaging software, raised €15M in Series B funding.

TheRound was led by Crédit Mutuel InnovationCapHorn with participation from Verve, Sham Innovation Santé, Omnes, IT-Translation, M-Capital and Région Sud Investissement.

The company intends to use the funds to accelerate its commercial presence in the United StatesMammoScreen will continue to develop new features.

LedBy CEO Matthieu Leclerc-Chalvet, Chief ScientificAnd Technology OfficerAnd Founder Pierre Fillard, TherapixelThe company is focused on the development and commercialization AI-powered medical imaging software with the goal to provide relevant information to healthcare professionals. TheMammoScreen is a software system that allows for the interpretation of mammograms in 2D and 3D.

ArmedTwo FDA regulatory clearances were obtained in the United StatedMammoScreen, which can be used for both 2D (tomosynthesis), and 3D (tomosynthesis), is already being used in large networks of breast cancer screening clinics. ItA score is used to indicate at a glance the suspicion level for a mammogram. ThisIt is possible to confirm lesions that have been confirmed and to save time by analyzing benign cases more quickly.



Leave a Comment